Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer : Impact on long-term outcome. Results of the phase II TAKO 05/ABCSG R‑02 trial.

Kogler, P; DeVries, AF; Eisterer, W; Thaler, J; Sölkner, L; Öfner, D; Strahlenther Onkol. 2018; 194(1): 41-49.

Rac GTPases in Hematological Malignancies

Durand-Onayli, V; Haslauer, T; Harzschel, A; Hartmann, TN INT J MOL SCI. 2018; 19(12): 4041

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer.

Huemer, F; Rinnerthaler, G; Westphal, T; Hackl, H; Hutarew, G; Gampenrieder, SP; Weiss, L; Greil, R; Oncotarget. 2018; 9(23):-16520

Risks and chances of aberrant DNA repair in cancer.

Schubert, M; Greil, R; Geisberger, R; Oncoscience. 2018; 5(9-10): 256-257.

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.

Greil, R; Pleyer, L; Jansko, B; Feierabend, C; Rettenbacher, L; Stiefel, O; Rass, C; Morre, P; Neureiter, D; Greil-Ressler, S; Oncotarget. 2018; 9(29): 20928-20940.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Melchardt, T; Magnes, T; Hufnagl, C; Thorner, AR; Ducar, M; Neureiter, D; Tränkenschuh, W; Klieser, E; Gaggl, A; Rösch, S; Rasp, G; Hartmann, TN; Pleyer, L; Rinnerthaler, G; Weiss, L; Greil, R; Egle, A; Eur J Cancer. 2018; 93:69-78

Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R; Ann Hematol. 2018; 97(10): 1825-1839.

Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer : A retrospective analysis.

Asamer, E; Szkandera, J; Gibiser, P; Lembeck, AL; Stojakovic, T; Kornprat, P; Lackner, C; Winder, T; Schlick, K; Stoger, H; Gerger, A; Pichler, M; Stotz, M WIEN KLIN WOCHENSCHR. 2018; 130(19-20): 569-574.

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Fuchs, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Bartsch, R; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R; BMC Cancer. 2018; 18(1): 1074

Does clinical outcome of birch pollen immunotherapy relate to induction of blocking antibodies preventing IgE from allergen binding? A pilot study monitoring responses during first year of AIT.

Huber, S; Lang, R; Steiner, M; Aglas, L; Ferreira, F; Wallner, M; Hawranek, T; Gadermaier, G; Clin Transl Allergy. 2018; 8: 39